<DOC>
	<DOCNO>NCT02753881</DOCNO>
	<brief_summary>Patients primary secondary liver cancer may participate study . The purpose perform analysis effect doxorubicin metabolite doxorubicinol body ( doxorubicin pharmacokinetics ) conventional transarterial chemoembolization ( cTACE ) . cTACE procedure chemotherapy drug inject , follow injection small bead block tumor-feeding artery . Doxorubicin chemotherapeutic agent use cTACE procedure . This study examine doxorubicin pharmacokinetics patient : 1 ) receive whole liver cTACE ; 2 ) receive super-selective CTACE ( i.e. , deliver close proximity tumor ) .</brief_summary>
	<brief_title>Pharmacokinetics Doxorubicin cTACE Liver Cancer</brief_title>
	<detailed_description>Patients primary secondary liver cancer may participate study . The purpose perform analysis effect doxorubicin metabolite doxorubicinol body ( doxorubicin pharmacokinetics ) conventional transarterial chemoembolization ( cTACE ) . A pharmacokinetics profile ( PK profile ) construct include peak plasma concentration ( Cmax ) , time maximum concentration ( TMax ) , area concentration curve ( AUC ) . This composite measure use compare patient cTACE lobar administration cTACE superselective administration . In addition , PK profile correlate toxicity , tumor burden , body surface area , gender . Feasibility safety also assess .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Histologically , cytologically , radiologically confirm liver dominant liver malignancy . 3 . Preserved liver function ( ChildPugh AB class ) without significant liver decompensation . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 study entry . 5 . Measurable evaluable disease directly treat intrahepatic therapy ( define Response Evaluation Criteria Solid Tumors [ RECIST ] 1.1 ) . 6 . Suitable TACE base blood parameter platelet count , bilirubin , international normalize ratio . 7 . May enrol history prior liver direct intraarterial therapy intraarterial therapy target lesion occur &gt; 1 year prior enrollment date . Intraarterial therapy different target within 1 year prior enrollment date exclude subject . 1 . Serum total bilirubin &gt; 3.0 mg/dL 2 . Creatinine &gt; 2.0 mg/dL 3 . Platelets &lt; 50000/µL 4 . Complete portal vein thrombosis reversal flow 5 . Ascites ( trace ascites image acceptable )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>